scholarly journals Study on Carcinomas of Breast with Special Reference to Expression of Vascular Endothelial Growth Factor and Her 2/neu

2021 ◽  
pp. 70-82
Author(s):  
Sharmistha Rout ◽  
. Varadaraju ◽  
A. Josephine ◽  
Vindu Srivastava
Keyword(s):  
Breast Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Breast Carcinoma ◽  
Tumour Size ◽  
Clinicopathological Parameters ◽  
Vascular Endothelial ◽  
Immunohistochemical Markers ◽  
Her 2 ◽  
Endothelial Growth Factor

Carcinoma is a major health issue worldwide. Breast cancer is by far the most common of all cancers diagnosed in women, in the world. The incidence of breast cancer has risen in India (22.9%). Breast cancer cases in India are expected to increase by 26% by 2020. There be existing 2,088,849 new cases of breast cancer worldwide foremost to 626,679 deaths in 2018. Among the Indian women, cancer cervix and breast carcinoma account for 60% of the total cases, of which the incidence of breast carcinoma is 10.4%. Angiogenesis is nothing but the growth of new vasculature from the pre-existing vasculature. This physiological process is involved in organ and embryonic development, wound healing, and reproductive functions in the adults. However, pathologically, angiogenesis is implicated in macular degeneration, rheumatoid arthritis, psoriasis, and tumour growth. HER2/neu status has recently become clinically very relevant because it has been demonstrated that HER-2/neu positive tumors have worse prognosis than HER2/neu negative tumors. To correlate the expressions of the Immunohistochemical markers HER-2/neu and Vascular Endothelial Growth factor (VEGF) with the various clinicopathological parameters like age, tumour size, histological type, grade, stage and lymph node metastasis status. It concludes an unequivocal association between the expressions of the two immunohistochemical markers, HER-2/neu and VEGF in breast carcinoma cases and its implication in guiding therapy against HER-2/neu over-expressing tumors.

Significance of serum vascular endothelial growth factor and cancer antigen 15.3 in patients with triple negative breast cancer

2013 ◽  
Vol 13 (1) ◽  
pp. 60-67 ◽  
Author(s):  
Priyanka Chanana ◽  
Awadesh Kumar Pandey ◽  
Budhi Singh Yadav ◽  
Jasbinder Kaur ◽  
Seema Singla ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Triple Negative ◽  
Tumour Size ◽  
Vascular Endothelial ◽  
Cancer Antigen ◽  
Ca 15.3 ◽  
Endothelial Growth Factor ◽  
Disease Parameters

AbstractBackgroundA pilot study was undertaken to find significance of vascular endothelial growth factor (VEGF) and cancer antigen (CA 15.3) in breast cancer patients.Materials and methodsTotal 70 patients with breast cancer were divided into triple negative breast cancer (TNBC) and non-TNBC depending on oestrogen receptors, progesterone receptors or HER-2/neu receptors status. Serum CA 15.3 and VEGF levels were evaluated with enzyme-linked immunosorbent assay at the time of diagnosis and were correlated with age, tumour size and stage of the disease in both the groups. Spearman's test was used to find the correlation.ResultsVEGF levels were found to be >400 pg/ml in 27 patients, 19 (54·33%) of them were TNBC and only 8 (22·87%) non-TNBC. Mean values of the VEGF were, 784·34 pg/ml in TNBC and 334·60 pg/ml non-TNBC patients, respectively. CA 15.3 level was found to be higher in non-TNBC group (60·72 U/ml) than in TNBC group (45·24 U/ml). In all patients significant correlation was found between serum CA 15.3 level and tumour size and stage of the disease. In non-TNBC patients significant correlation was seen between CA 15.3 values and stage of the disease, but VEGF had no correlation with any of the disease parameters. In TNBC patients, there was no correlation between CA 15.3 level and any of the disease parameters but VEGF showed a significant correlation with both tumour size and stage of the disease.ConclusionExpression profile of VEGF was high in TNBC than non-TNBC patients. VEGF serves to be a better biomarker as compared with CA 15.3 in TNBC patients.

Expression of periostin in human breast cancer: Biological and clinico-pathological correlations

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21090-21090
Author(s):  
F. Puglisi ◽  
A. Minisini ◽  
C. Andreetta ◽  
S. Russo ◽  
E. Pegolo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Breast Carcinoma ◽  
Rank Test ◽  
Consecutive Series ◽  
Vascular Endothelial ◽  
Immunohistochemical Expression ◽  
Ki 67 ◽  
Endothelial Growth Factor

21090 Background: Mesenchyme-specific genes are highly expressed by various types of human cancers. Recent lines of evidence suggest that periostin, a myoepithelial/basal gene, may play a role in the biology of breast cancer. Periostin is involved in metastatic process by taking part in mechanisms of adhesion and migration of epithelial cells. Furthermore, periostin seems to have a role in tumor angiogenesis through the up-regulation of vascular endothelial growth factor receptors in endothelial cells. We aimed at investigating the immunohistochemical expression of periostin in breast cancer and its correlation with established biological and prognostic factors. Methods: We performed immunohistochemical analysis of periostin in a consecutive series of 206 tumor samples from 200 patients with early breast carcinoma. To this aim, we used a specific antiperiostin antibody (Biovendor Laboratory Medicine, Inc., Palackeho 56, 612 00 Brno, Czech Republic). The intensity of immunoreactivity was scored as 0, 1, 2 or 3 denoting negative, weak, moderate and strong staining, respectively. Therefore, for statistical analysis, the periostin expression level for each case was putatively defined as positive if the predominant intensity was =1. We also analyzed immunohistochemical expression of Ki-67 (MIB-1), HER-2/neu, VEGF, VEGFR-1 and VEGFR- 2. Results: Periostin was found to be highly expressed by carcinoma cells, whereas it was absent in normal breast tissues. The pattern of expression was mainly cytoplasmic, although in some cases (11%) a nuclear reactivity was observed. A cytoplasmic expression was found in 108 out of 189 (57%) evaluable cases. Interestingly, a significant correlation was found between periostin expression and VEGF and VEGFR-1 (Spearman's rank test rho =0.37, p <0.0001 and rho=0.26, p=0.0005, respectively). Conclusions: These results strengthen the hypothesis of a relationship between periostin and vascular endothelial growth factor system. The role of periostin in angiogenesis and in other relevant molecular pathways in breast carcinoma deserves to be further investigated. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document